bispecific antibodies enable synthetic agonistic receptor t-cell therapy in melanoma
Published 1 year ago • 105 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
30:36
bispecific antibodies to engage vγ9vδ2-t cells for cancer immunotherapy
-
4:26
what are bispecific antibodies?
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
3:40
metastatic melanoma: mart-1 t-cell receptor modified t-cells
-
14:00
what are bispecific antibodies?
-
0:24
how bispecific antibodies work
-
3:00
drawn to science | t-cell bispecific antibodies
-
21:32
bispecific antibodies for t‐cell redirection therapy
-
1:10
how bispecific antibodies contribute to t-cell activation in aml
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
6:18
mechanism of action of tmod™ t-cell therapy and pre-clinical evidence
-
1:38
bispecific antibodies, technics use in immunotherapy
-
1:26
moffitt medical minute (ep. 43) - bispecific antibodies (bsabs) in cancer treatment
-
10:54
bispecific antibody therapy
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
4:45
bispecifics part 2: monoclonal and bispecific antibodies
-
0:55
what are bispecific antibodies?
-
49:07
a mucin 16 bispecific t cell-engaging antibody for the treatment of ovarian cancer